Context Therapeutics (CNTX) Cash & Equivalents (2020 - 2026)

Context Therapeutics has disclosed Cash & Equivalents across 7 years of filings, most recently posting $54.5 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $54.5 million, down 38.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.5 million (down 38.97% YoY), and the FY2025 annual result was $66.0 million, down 30.11% from the prior year.
• Cash & Equivalents came in at $54.5 million for Q1 2026 at Context Therapeutics, down from $66.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $101.5 million in Q2 2024 to a low of $10.1 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $45.7 million (2022), against an average of $53.9 million.
• Across the five-year window, Cash & Equivalents jumped 9299.93% in 2022 and slumped 66.11% in 2024, its largest moves.
• Context Therapeutics' Cash & Equivalents stood at $35.5 million in 2022, then sank by 59.29% to $14.4 million in 2023, then soared by 553.5% to $94.4 million in 2024, then slumped by 30.11% to $66.0 million in 2025, then dropped by 17.37% to $54.5 million in 2026.
• The last three Cash & Equivalents figures came in at $54.5 million (Q1 2026), $66.0 million (Q4 2025), and $76.9 million (Q3 2025), per Business Quant data.